News & Updates
Filter by Specialty:
Biweekly cabazitaxel plus G-CSF beneficial to certain older mCRPC patients
In the treatment of older patients with metastatic castration-resistant prostate cancer (mCRPC) who are considered unsuitable candidates for standard cabazitaxel (CBZ) regimens, treatment with CBZ at 16 mg/m2 (biweekly CBZ16) plus prophylactic granulocyte colony–stimulating factor (G-CSF) at each cycle helps reduce the risk of higher grade neutropenia and/or neutropenic complications while yielding similar clinical outcomes, according to the results of the phase III CABASTY trial.
Biweekly cabazitaxel plus G-CSF beneficial to certain older mCRPC patients
27 Nov 2023
177Lu-PSMA-617 improves rPFS vs ARPI switch in taxane-naïve mCRPC patients
The prostate-specific membrane antigen (PSMA)–targeted radioligand, lutetium-177 (177Lu)–PSMA-617, improves radiographic progression-free survival (rPFS) vs androgen receptor pathway inhibitor (ARPI) switch and has a favourable safety profile in taxane-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on one prior second-generation ARPI, results of the phase III PSMAfore trial have shown.
177Lu-PSMA-617 improves rPFS vs ARPI switch in taxane-naïve mCRPC patients
14 Nov 2023
Multimodal intervention reduces second-line antibiotic prescriptions for UTI
A multimodal intervention applied in general practice results in a significant decrease in antibiotic prescribing and an increase in guideline adherence among women with uncomplicated urinary tract infection (UTI), a study has shown.
Multimodal intervention reduces second-line antibiotic prescriptions for UTI
13 Nov 2023
Serum vitamin A, E forms tied to prostate cancer risk
Several forms of serum vitamin A and E were associated with prostate cancer risk, with significant effect modification by smoking and alcohol consumption status, according to an analysis that used data from the Singapore Prostate Cancer Study.